Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents for Use in COVID-19 Patients.

Hari Hara Sudhan LakshmananAdity A PoreTia C L KohsFeyza YazarRachel M ThompsonPatrick L JurneyJeevan MaddalaSven R OlsonJoseph J ShatzelSiva A VanapalliOwen J T McCarty

Published in: Cellular and molecular bioengineering (2020)

Safe and effective mitigating agents are needed for treatment and prevention of thrombotic complications in COVID-19 patients. This simple microfluidic device holds potential to be developed into a tool for assessing the effects of anticoagulant therapy on hemostasis.

Keyphrases

circulating tumor cells
atrial fibrillation
high throughput
sars cov
single cell
label free
risk factors
stem cells
risk assessment
mesenchymal stem cells
smoking cessation